Company news
ImmuPharma plc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Update on LupuzorT Pivotal Phase III Study
November 2, 2017
Completion of Lanstead Sharing Agreement
October 4, 2017
Preparation of Lupuzor'sT Regulatory Submissions
September 26, 2017
Notification of Interim Results
September 19, 2017
AIM Rule 17 Notice
August 18, 2017
Annual Report & Notice of AGM
June 7, 2017
Notification of Full Year Results
May 22, 2017
Update on Lupuzor Phase III Study
May 17, 2017
New Employee Share Option Plan & Grant of Options
March 31, 2017
ImmuPharma to present at Master Investor Show
March 24, 2017
£4.1 Million Fund Raise via Accelerated Bookbuild
March 10, 2017
Change of Adviser
January 24, 2017
Update on Lupuzor Pivotal Phase III Study
December 22, 2016
Update on Cancer Compound IPP-204106 'Nucant'
November 16, 2016
Close of Accelerated Bookbuild
October 21, 2016
Half-year Report
September 30, 2016
Update on Lupuzor's pivotal phase III study
September 14, 2016
Symposium with Lupuzors Inventor Prof. S Muller
June 8, 2016
European Patients Commence Dosing in Lupuzor
June 7, 2016
Annual Financial Report & Notice of AGM
May 4, 2016
Notice of Results
April 26, 2016
First European Site Opens - Patient Recruitment
March 9, 2016
EIS and VCT Qualifying Status and Issue of Equity
March 1, 2016
Issue of Equity
February 24, 2016
Result of GM
February 22, 2016
US patients commence dosing in phase III study
February 15, 2016
Placing and Subscription Raises £8.3 million
February 5, 2016
ImmuPharma & Simbec-Orion - Investigators Meeting
December 15, 2015
Update on the progress of Lupuzor
December 7, 2015
Lupuzor Phase III Pivotal Trial Update
November 4, 2015
Richard Warr
July 29, 2015
Term Sheet signed $14 million funding for Lupuzor
July 27, 2015
Lupuzor's Founder Dr Slyviane Muller Awarded Medal
June 25, 2015
Annual Report & Accounts
May 6, 2015
Preliminary Results
April 30, 2015
Cancer update: IPP-204106
February 11, 2015
Enterprise Investment Scheme Status
January 27, 2015
Collaboration Agreement with Simbec-Orion
January 22, 2015
Additional Listing - Conditional Placing
October 21, 2014
ImmuPharma awarded EUR400,000 Grant
October 20, 2014
Half Yearly Report
September 30, 2014
Access to pioneering research in Bordeaux France
June 27, 2014
New nucant patents
June 16, 2014
Annual Financial Report
May 23, 2014
Dr. Sylviane Muller - Presentation Abstract
May 6, 2014
Dr. S Muller, founder of Lupuzor presentation.
April 23, 2014
ImmuPharma Sponsors the 2014 European Lupus Confer
April 11, 2014
Additional Listing
October 14, 2013
Update cancer programme IPP-204106
August 13, 2013
FDA grants ImmuPharma amended SPA
July 31, 2013
Calls
Decks
- Investor Presentation (April 2020)
Investor deck · 15 slides · April 2020